Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition

2006897 citationsJournal Articlebronze Open Access

Authors

Raphaela Goldbach‐Mansky · National Institute of Arthritis and Musculoskeletal and Skin Diseases

Natalie Dailey Garnes · National Institutes of Health

Scott Canna · National Institute of Arthritis and Musculoskeletal and Skin Diseases

A Gelabert · National Institutes of Health

Janet H. Jones · National Institute of Arthritis and Musculoskeletal and Skin Diseases

Benjamin I. Rubin · National Eye Institute

Abstract

Daily injections of anakinra markedly improved clinical and laboratory manifestations in patients with neonatal-onset multisystem inflammatory disease, with or without CIAS1 mutations. (ClinicalTrials.gov number, NCT00069329 [ClinicalTrials.gov].).

Topics & Keywords

Inflammasome and immune disorders Immune Response and Inflammation Streptococcal Infections and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 355, Issue 6, pp. 581-592

DOI: 10.1056/nejmoa055137

Field-Weighted Citation Impact: 26.16